

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Fred Hutchinson Cancer Center Antibody Technology Core Facility

RRID:SCR_022608

Type: Tool

Proper Citation

Fred Hutchinson Cancer Center Antibody Technology Core Facility (RRID:SCR_022608)

Resource Information

URL: <https://www.fredhutch.org/en/research/shared-resources/core-facilities/antibody-technology.html>

Proper Citation: Fred Hutchinson Cancer Center Antibody Technology Core Facility (RRID:SCR_022608)

Description: Designs campaign strategies for generation and identification of novel monoclonal antibody compositions. Our projects encompass range of applications in oncology, viral therapeutics and diagnostics.

Synonyms: Fred Hutchinson Cancer Center Antibody Technology, Fred Hutchinson Cancer Center Antibody Technology Shared Resource

Resource Type: access service resource, core facility, service resource

Keywords: novel monoclonal antibody, oncology, viral therapeutics and diagnostics projects, ABRF, USEDit, NACCSR

Availability: Open

Resource Name: Fred Hutchinson Cancer Center Antibody Technology Core Facility

Resource ID: SCR_022608

Alternate IDs: ABRF_1538

Alternate URLs: https://coremarketplace.org/RRID:SCR_022608/?citation=1

Record Creation Time: 20220802T050144+0000

Record Last Update: 20260905T133427+0000

Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Antibody Technology Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Antibody Technology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hagen MW, et al. (2026) The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy. *Blood advances*, 10(7), 2452.

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. *Cell reports. Medicine*, 7(2), 102618.

Sehgal P, et al. (2025) NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas. *Cell reports*, 44(8), 116099.

Belmont L, et al. (2024) Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection. *Journal of virology*, 98(11), e0158224.

Contreras M, et al. (2024) Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies. *mBio*, 15(2), e0304823.

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. *Cell reports*, 43(10), 114811.

Whiteaker JR, et al. (2024) Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometry. *Scientific data*, 11(1), 682.

Belmont L, et al. (2024) Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection. *bioRxiv : the preprint server for biology*.

Lubow J, et al. (2023) Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses. *PLoS pathogens*, 19(10), e1011722.

Davidson KA, et al. (2023) Centralspindlin proteins Pavarotti and Tumbleweed along with WASH regulate nuclear envelope budding. *The Journal of cell biology*, 222(8).

Kikawa C, et al. (2023) The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies. *bioRxiv : the preprint server for biology*.

Kikawa C, et al. (2023) The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies. *Journal of virology*, 97(11), e0141423.

Lubow J, et al. (2023) Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses. *bioRxiv : the preprint server for biology*.